Health Canada to Review AMX0035 as ALS Treatment

Health Canada to Review AMX0035 as ALS Treatment

305279

Health Canada to Review AMX0035 as ALS Treatment

Health Canada has agreed to review Amylyx Pharmaceuticals‘ application seeking approval of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). “We are pleased that our submission has been accepted for review by Health Canada, and we are committed to serving those affected by ALS in the country,” Chris Aiello, general manager and head of Canada at Amylyx, said in a press release. This “news marks another milestone in our efforts to bring a potential…

You must be logged in to read/download the full post.